Observations From Long Term Responders in the Gefitinib (Iressa) Expanded Access Program (EAP)

AstraZeneca

Status: Completed

Conditions: Non-Small Cell Lung Cancer

Study type: Observational

Funder types: Industry

Identifiers

NCT01103089

NIS-ONL-IRE-2009/1

Details and patient eligibility

About

The purpose of the study is to determine patient characteristics from patients that have used Iressa for a period of minimal 3 years.

Enrollment: 10 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Participation in the gefitinib Expanded Access Program
• Patient still uses gefitinib in September 2009